PTC Therapeutics (PTCT) Delnica Cena

PTC Therapeutics Cena

NASDAQ·ZAPRTO
60,97
​
Trg je zaprt

Prihodki so rasli 48,3 % letno v zadnjih 23 letih na 1,73 Mrd. USD. čista marža družbe PTC Therapeutics je zdaj 39,4 %, narasla z −97,3 % pred nekaj leti. Mediana ciljne cene analitikov je 108,00 USD, torej nad trenutno ceno za 77,1 %. Od 21 analitikov jih 18 priporoča nakup — skupni konsenz je Nakup.

Cena delnice PTC Therapeutics

Do teh podatkov prek Eulerpool API

100.000 zahtevkov/mes. brezplačno · brez kartice

PTC Therapeutics poslovni model in analiza delnice

PTC Therapeutics Inc. je biotehnološko podjetje s sedežem v South Plainfieldu, New Jersey. Podjetje je bilo ustanovljeno leta 1998 in se osredotoča na raziskave ter razvoj zdravil za zdravljenje redkih bolezni. PTC Therapeutics ima dva glavna oddelka: raziskave in razvoj izdelkov ter znanost in inovacije. Njegov portfelj vključuje več zdravil za zdravljenje redkih bolezni, kot so Duchennova mišična distrofija, spinalna mišična atrofija in cistična fibroza. Eden ključnih izdelkov podjetja je Translarna, prvo zdravilo, ki cilja na RNA in je odobreno za zdravljenje Duchennove mišične distrofije. Drug pomemben izdelek je Evrysdi, odobren za zdravljenje spinalne mišične atrofije. PTC Therapeutics ima tudi vrsto zdravil v fazi kliničnih preskušanj za različne redke bolezni. Podjetje si prizadeva spodbujati inovacije in vzdržuje partnerstva z akademskimi institucijami ter drugimi podjetji za raziskovanje in razvoj novih terapij. Svojim pacientom z redkimi boleznimi želi izboljšati življenje prek inovativnih zdravljenj.

Pogosto postavljena vprašanja o delnici PTC Therapeutics

PTC Therapeutics Inc.'s business model revolves around researching, developing, and commercializing innovative therapies for rare genetic disorders. The company focuses on utilizing its expertise in RNA biology and small molecule pharmacology to develop treatments that address the underlying cause of diseases. PTC Therapeutics Inc. aims to increase the production of functional proteins in patients with genetic disorders by targeting RNA splicing or protein translational regulation. Through strategic partnerships, clinical trials, and regulatory approvals, PTC Therapeutics Inc. strives to bring transformative treatments to patients with limited therapeutic options, ultimately improving their quality of life.

PTC Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of PTC Therapeutics Inc in the market are companies like Sarepta Therapeutics, Vertex Pharmaceuticals, and BioMarin Pharmaceutical.

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of orally administered small molecule drugs. Founded in 1998, PTC Therapeutics initially focused on RNA biology and identified a new class of RNA-modulating small molecules. Since its inception, the company has been committed to addressing the unmet medical needs of patients with rare and genetic disorders. Today, PTC Therapeutics is a global leader in the development of treatments for rare diseases, with a portfolio that includes multiple therapies targeting various genetic mutations. Through its innovative approach, PTC Therapeutics aims to improve the lives of patients worldwide.

PTC Therapeutics Inc has achieved several significant milestones. One notable accomplishment includes the approval of their drug, Translarna™ (ataluren), by the European Medicines Agency (EMA). This groundbreaking treatment is designed to address the underlying cause of nonsense mutation Duchenne muscular dystrophy (nmDMD). Additionally, PTC Therapeutics Inc has successfully expanded its global footprint by establishing commercialization agreements for Translarna™ in various countries. These achievements highlight PTC Therapeutics Inc's commitment to advancing innovative therapies and improving the lives of patients with genetic disorders like nmDMD.

PTC Therapeutics Inc is primarily present in various countries and regions across the globe. As a pharmaceutical company, PTC Therapeutics Inc operates in multiple markets to ensure patient access to its innovative therapies. The company's presence extends to regions such as North America, including the United States and Canada, as well as Europe, with a focus on countries like Germany, France, and Italy. PTC Therapeutics Inc continues to expand its presence in other international markets, driven by its commitment to improving the lives of patients worldwide.

PTC Therapeutics Inc represents core values of innovation, dedication, and patient-centricity. With a strong corporate philosophy, the company is committed to developing transformative therapies for patients with rare diseases caused by genetic mutations. PTC Therapeutics Inc focuses on leveraging cutting-edge science and technology to develop targeted treatments, addressing unmet medical needs. By fostering collaboration and embracing a patient-first approach, PTC Therapeutics Inc strives to improve the quality of life for individuals and families affected by these rare and debilitating conditions. Through their relentless pursuit of scientific advancements, PTC Therapeutics Inc demonstrates their commitment to making a meaningful difference in the lives of patients worldwide.

Analitiki trenutno določajo povprečno ciljno ceno 106,14 USD za delnico PTC Therapeutics (mediana: 108,00 USD), kar pomeni +74,1 % glede na zadnjo ceno. Konsenz temelji na 21 ocenah.

21 analitikov trenutno ocenjuje delnico PTC Therapeutics: 18 priporoča nakup, 3 držanje in 0 prodajo. Za 2026 analitiki pričakujejo, da bo PTC Therapeutics ustvaril prihodke 1,32 Mrd. USD in dobiček na delnico 0,93 USD.

Po trenutnem tečaju se delnica PTC Therapeutics trguje po 55,40 EUR (60,97 USD).

Delnica PTC Therapeutics (PTCT) je uvrščena na 5 borzah, med njimi: NASDAQ (PTCT), SIX (Zürich) (P91.SW), Frankfurt (BH3.F), München (BH3.MU), Düsseldorf (BH3.DU).

PTC Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapies for rare diseases. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey, USA. PTC Therapeutics Inc offers various products and solutions to treat diseases and conditions that are often neglected due to their rarity. These products are offered in three main areas: transcriptional regulation, DNA modification, and RNA technology. The products range from drugs to diagnostic tests to medical devices. In the transcriptional regulation division, PTC Therapeutics Inc is working on the development of small molecule drugs to regulate genes associated with various genetic diseases such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The most well-known product developed in this area is Translarna (Ataluren), which is approved for the treatment of Duchenne muscular dystrophy. The second area, DNA modification, focuses on developing therapies to correct targeted mutations in the genome. This includes the CRISPR/Cas9 system, which enables targeted genome editing. Along with RNA technology, which is the focus of the third area of the company, new possibilities for treating rare diseases are emerging. PTC Therapeutics Inc has already entered into various collaborations with biotech companies such as GenEdit, Censa Pharmaceuticals, and Beam Therapeutics. Another important core product of PTC Therapeutics Inc is the SMA360 diagnostic test, which aims to identify newly diagnosed infants and toddlers with spinal muscular atrophy (SMA). SMA360 is being developed in collaboration with Invitae and Biogen, and it enables fast and precise diagnosis of SMA. Due to its advanced pipeline and diversified product portfolio, PTC Therapeutics Inc has already achieved several milestones. In 2018, the company received approval for Emflaza in the US, a drug for the treatment of DMD. Further clinical trials are in the development phase. In terms of PTC Therapeutics Inc's business model, the development and commercialization of therapies for rare diseases are an important part. PTC Therapeutics Inc has a diversified product portfolio consisting of drugs, diagnostic tests, and medical devices. The company also collaborates with other companies in the biotech industry and partners with startups and universities in the research and development field. PTC Therapeutics Inc has experienced impressive growth in recent years and has the potential to develop and implement innovative therapies and solutions for rare diseases. The company has not only drawn interest in the industry but also from investors and is facing promising challenges in the future.

pričakovane prihodki za PTC Therapeutics znašajo 1,32 Mrd. USD. Ta vrednost temelji na trenutnih finančnih podatkih in odraža poslovno uspešnost podjetja.

pričakovane dobiček za PTC Therapeutics znaša 75,07 Mio. USD. Čisti dobiček odraža donosnost podjetja po odbitku vseh stroškov.

Razmerje cena-dobiček (P/E) PTC Therapeutics je trenutno 65,53. Razmerje P/E primerja trenutno ceno delnice z dobičkom na delnico in pomoči vlagateljem oceniti vrednost delnice PTC Therapeutics.

Razmerje cena-prihodki (P/S) PTC Therapeutics je trenutno 3,73. Razmerje P/S primerja tržno vrednost s celotnimi letnimi prihodki in služi kot kazalnik vrednotenja delnice PTC Therapeutics.

Eulerpool ocena kvalitete za PTC Therapeutics je 6/10.

ISIN PTC Therapeutics je US69366J2006. ISIN (International Securities Identification Number) je svetovni edinstven identifikator za vrednostne papirje.

WKN PTC Therapeutics je A1W0MW. WKN (Wertpapierkennnummer) je šestmestna nemška oznaka za identifikacijo vrednostnih papirjev.

Ticker PTC Therapeutics je PTCT. Ticker simbol se uporablja za trgovanje z delnicami PTC Therapeutics na borzi.

Poštena vrednostTerminal
50,00 USD
Precenjenost/podcenjenostTerminal
Pošteno ocenjena
Sektor
Industrija
Biotehnologija
Število delnic
Zaposleni
Prihodki na zaposlenega
1,75 Mio. USD
Rast prihodkov Ø5 let
Rast EBIT Ø5 let
Rast neto dohodka Ø5 let
Spletna stran ptcbio.com
Valuta
USD
Javna ponudba delnic
20. jun. 2013
ISIN
US69366J2006
CUSIP
69366J200
SEDOL
B17VCN9
Tržna kapitalizacija
Razpon 52 tednov
AAQS
6 / 10
PEG
0,17
P/E razmerje
KGVe 2026
65,21
KGVe 2027
19,11
KGVe 2028
13,92
KGVe 2029
13,41
KGVe 2030
11,00
P/S
KUVe
3,73
EV/EBIT
7,73
KBV
3404,23
ROE (Donosnost kapitala)
ROA (Donosnost sredstev)
ROCE (Donosnost porabljenega kapitala)
ROIC (Donosnost vloženega kapitala)
27,29 %
Zadnja posodobitev 17. nov. 2026, 13:44

PTC Therapeutics Ticker

DÜSSELDORF · BH3.DUFRANKFURT · BH3.FMÜNCHEN · BH3.MUNASDAQ · PTCTSIX · P91.SW

PTC Therapeutics FIGI

PTCTGBP:XW · BBG00K88DWP7PTCT:US · BBG000QT15P7PTCT:UA · BBG004KT9791PTCT:UC · BBG004KT97C7PTCT:UN · BBG004KT97G3PTCT:UP · BBG004KT97J0PTCT:UB · BBG004KT97P3PTCT:UM · BBG004KT97S0PTCT:UX · BBG004KT97V6PTCT:UD · BBG004KT9871PTCT:UW · BBG004KT98C5PTCT:UF · BBG004KT98F2